UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
Amendment No.: *
Name of Issuer: NPS Pharmaceuticals, Inc.
Title of Class of Securities: Common Stock
CUSIP Number: 62936P103
(Date of Event Which Requires Filing of this Statement)
August 15, 2000
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
/ / Rule 13d-1(b)
/X / Rule 13d-1(c)
/ / Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect
to the subject class of securities, and for any subsequent
amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page
shall not be deemed to be "filed" for the purpose of
Section 18 of the Securities Exchange Act of 1934 ("Act") or
otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act
(however, see the Notes).
<PAGE>
CUSIP Number: 62936P103
1. Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Stuart T. Weisbrod
2. Check the Appropriate Box if a Member of a Group
a.
b. X
3. SEC Use Only
4. Citizenship or Place of Organization
United States
Number of Shares Beneficially Owned by Each Reporting Person
With:
5. Sole Voting Power:
25,000
6. Shared Voting Power:
1,220,200
7. Sole Dispositive Power:
25,000
8. Shared Dispositive Power:
1,220,200
9. Aggregate Amount Beneficially Owned by Each Reporting
Person
1,245,200
10. Check Box if the Aggregate Amount in Row (9) Excludes
Certain Shares
11. Percent of Class Represented by Amount in Row (9)
5.00%
-2-
<PAGE>
12. Type of Reporting Person
IN
-3-
<PAGE>
CUSIP Number: 62936P103
1. Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Merlin BioMed Investment Advisors, L.L.C.
2. Check the Appropriate Box if a Member of a Group
a.
b. X
3. SEC Use Only
4. Citizenship or Place of Organization
Delaware
Number of Shares Beneficially Owned by Each Reporting Person
With:
5. Sole Voting Power:
6. Shared Voting Power:
889,700
7. Sole Dispositive Power:
8. Shared Dispositive Power:
889,700
9. Aggregate Amount Beneficially Owned by Each Reporting
Person
889,700
10. Check Box if the Aggregate Amount in Row (9) Excludes
Certain Shares
11. Percent of Class Represented by Amount in Row (9)
3.57%
-4-
<PAGE>
12. Type of Reporting Person
IA
-5-
<PAGE>
CUSIP Number: 62936P103
1. Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Merlin BioMed Group, L.L.C.
2. Check the Appropriate Box if a Member of a Group
a.
b. X
3. SEC Use Only
4. Citizenship or Place of Organization
Delaware
Number of Shares Beneficially Owned by Each Reporting Person
With:
5. Sole Voting Power:
6. Shared Voting Power:
330,500
7. Sole Dispositive Power:
8. Shared Dispositive Power:
330,500
9. Aggregate Amount Beneficially Owned by Each Reporting
Person
330,500
10. Check Box if the Aggregate Amount in Row (9) Excludes
Certain Shares
11. Percent of Class Represented by Amount in Row (9)
1.32%
-6-
<PAGE>
12. Type of Reporting Person
CO
-7-
<PAGE>
Item 1(a) Name of Issuer: NPS Pharmaceuticals, Inc.
(b) Address of Issuer's Principal Executive Offices:
420 Chipeta Way, Suite 240
Salt Lake City, UT 84108-1256
Item 2(a) - (c). Name, Principal Business Address, and
Citizenship of Persons Filing:
Stuart T. Weisbrod ("SW")
Merlin BioMed Investment Advisors, L.L.C. ("MBIA")
Merlin BioMed Group, L.L.C. ("MBG")
230 Park Avenue, Suite 928
New York, New York 10169
Stuart T. Weisbrod is a citizen of the United
States.
Merlin BioMed Investment Advisors, L.L.C. is a
Delaware limited liability company.
Merlin BioMed Group, L.L.C. is a Delaware limited
liability company.
(d) Title of Class of Securities: Common Stock
(e) CUSIP Number: 62936P103
Item 3. If this statement is filed pursuant to Rule
13d-1(b)(1) or 13d-2(b) or (c) check whether the person
filing is:
(a) / / Broker or dealer registered under Section 15 of
the Act,
(b) / / Bank as defined in Section 3(a)(6) of the Act,
(c) / / Insurance Company as defined in
Section 3(a)(19) of the Act,
(d) / / Investment Company registered under Section 8
of the Investment Company Act,
(e) / / Investment Adviser registered under Section 203
of the Investment Advisers Act of 1940,
-8-
<PAGE>
(f) / / Employee Benefit Plan, Pension Fund which is
subject to the provisions of the Employee
Retirement Income Security Act of 1974 or
Endowment Fund,
(g) / / Parent Holding Company, in accordance with Rule
13d-1(b)(ii)(G),
(h) / / Savings association as defined in Section 3(b)
of the Federal Deposit Insurance Act,
(i) / / Church plan excluded from the definition of an
investment company under Section 3(c)(14) of
the Investment Company Act,
(j) / / Group, in accordance with Rule 13d-
1(b)(1)(ii)(H).
If this statement is filed pursuant to Rule 13d-1(c), check
this box. / X /
Item 4. Ownership.
(a) Amount Beneficially Owned: SW - 1,245,200
shares; MBIA - 889,700 shares; MBG - 330,500
shares of Common Stock (the "Shares").
(b) Percent of Class: SW - 4.86%; MBIA - 3.57%;
MBG - 1.32%;
(c) SW - 1,220,200 shares with shared power to vote
or to direct the vote; 25,000 shares with sole
power to vote or to direct the vote; 1,220,200
shares with shared power to dispose or to
direct the disposition of; 25,000 shares with
the sole power to dispose or to direct the
disposition of
MBIA - 889,700 shares with shared power to vote
or to direct the vote; 0 shares with sole power
to vote or to direct the vote; 889,700 shares
with shared power to dispose or to direct the
disposition of; 0 shares with the sole power to
dispose or to direct the disposition of
MBG - 330,500 shares with shared power to vote
or to direct the vote; 0 shares with sole power
-9-
<PAGE>
to vote or to direct the vote; 330,500 shares
with shared power to dispose or to direct the
disposition of; 0 shares with the sole power to
dispose or to direct the disposition of
Item 5. Ownership of Five Percent or Less of a Class.
N/A
Item 6. Ownership of More than Five Percent on Behalf of
Another Person.
N/A
Item 7. Identification and Classification of the Subsidiary
Which Acquired the Security Being Reported by the
Parent Holding Company.
N/A
Item 8. Identification and Classification of Members of the
Group.
N/A
Item 9. Notice of Dissolution of the Group.
N/A
Item 10.
Certification for Rule 13d-1(c): By signing below I
certify that, to the best of my knowledge and belief, the
securities referred to above were not acquired and are not
held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and
were not acquired and are not held in connection with or as
a participant in any transaction having that purpose or
effect.
After reasonable inquiry and to the best of my
knowledge and belief, each of the undersigned
certifies that the information set forth in this
statement is true, complete and correct.
-10-
<PAGE>
/s/ Stuart T. Weisbrod
____________________________
By: Stuart T. Weisbrod
MERLIN BIOMED INVESTMENT ADVISORS, L.L.C.
/s/ Stuart T. Weisbrod
_________________________
By: Stuart T. Weisbrod, Managing Member
MERLIN BIOMED GROUP, L.L.C.
/s/ Stuart T. Weisbrod
_________________________
By: Stuart T. Weisbrod, Managing Member
Date: August 15, 2000
-11-
<PAGE>
AGREEMENT
The undersigned agree that this Schedule 13G dated August
15, 2000 relating to the Common Stock of NPS Pharmaceuticals,
Inc. shall be filed on behalf of the undersigned.
/s/ Stuart T. Weisbrod
____________________
By: Stuart T. Weisbrod
MERLIN BIOMED INVESTMENT ADVISORS,
L.L.C.
/s/ Stuart T. Weisbrod
_____________________________
By: Stuart T. Weisbrod, Managing
Member
MERLIN BIOMED GROUP, L.L.C.
/s/ Stuart T. Weisbrod
_____________________________
By: Stuart T. Weisbrod, Managing
Member
-12-
02081001.AJ2
